Searching…
Is Amneal Pharmaceuticals (NASDAQ:AMRX) the best stock in the MED - DRUGS industry? Compare top AMRX competitors at MarketBeat.
One of the most prominent areas where Amneal faces competition is in the generic pharmaceuticals market. Multiple sources from synapse‐provided documents consistently identify key players that dominate this segment: T...
Compare Amneal Pharmaceuticals to its competitors by revenue, employee growth and other metrics at Craft.
Amneal Pharmaceuticals (AMRX) just received U.S. FDA approval for its iohexol injection, paving the way for the first generic alternative to Omnipaque in a $652 million market. This milestone ...
Amneal Pharmaceuticals Inc Competitors and Alternatives, including their financial performance and stock comparison.
View Amneal Pharmaceuticals's top competitors like Aurobindo Pharma, Cadence Pharmaceuticals - Now a Part of Mallinckrodt Pharmaceuticals, and Hikma Pharmaceuticals.
Amneal's top competitors include Sun Pharma, Mylan and Dr.Reddy's. See the full list of Amneal alternatives and competitive updates on Owler, the world’s largest community-based business insights platform.
Who are Amneal Pharmaceuticals's biggest competitors? Compare Amneal Pharmaceuticals vs. main competitors.
Founded in 2002, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes a diverse portfolio of pharmaceuticals. Amneal reported revenues of $730.5 million, up 18.4% year on year. This print exce...
Amneal Pharmaceuticals competitors are Amgen, Gilead Sciences, Impax Laboratories, and more. Learn more about Amneal Pharmaceuticals's competitors and alternatives by exploring information about those companies.
